Varian Medical Systems Completes Acquisition of Velocity Software Platform | Varian

{ "pageType": "news-article", "title": "Varian Medical Systems Completes Acquisition of Velocity Software Platform", "articleDate": "04 April 2014", "introText": "", "category": "Corporate and Financial Releases" }

Varian Medical Systems Completes Acquisition of Velocity Software Platform

PALO ALTO, Calif. and ATLANTA, April 4, 2014 /PRNewswire/ -- Varian Medical Systems (NYSE:VAR) today announced it has completed the acquisition of certain assets of Velocity Medical Solutions, LLC, a privately-held Atlanta-based developer of specialized software for cancer clinics. 

As previously announced, the acquisition includes software that enables clinicians to aggregate unstructured treatment and imaging data from diverse systems, and to use this information to make more informed treatment decisions. *

Varian will continue development of this oncology software platform with the Velocity team in Atlanta, Georgia.  Financial terms of the asset acquisition are not being disclosed. 

*Velocity products may not be available in all markets.

About Varian Medical Systems
Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes, digital detectors, and image processing workstations for X-ray imaging in medical, scientific, and industrial applications and also supplies high-energy X-ray devices for cargo screening and non-destructive testing applications.  Varian Medical Systems employs approximately 6,400 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit www.varian.com or follow us on Twitter.

Forward-Looking Statements
Except for historical information, this news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning industry outlook, including growth drivers; the company's future orders, revenues or other financial performance; the ability of the company's technology and products to treat cancer; and any statements using the terms "will," "plan," "expect," "estimated," or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results to differ materially from those anticipated. Such risks and uncertainties include the effect of global economic conditions; demand for the company's products; the company's ability to develop, commercialize, and deploy new products; the company's ability to meet legal and regulatory requirements; changes in the legal or regulatory environment; and the other risks listed from time to time in the company's filings with the Securities and Exchange Commission, which by this reference are incorporated herein. The company assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

FOR INFORMATION CONTACT:
Meryl Ginsberg, 650-424-6444
meryl.ginsberg@varian.com

SOURCE Varian Medical Systems